FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:1342-1349 October 24, 2002 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations.

After an overnight fast, an asymptomatic 45-year-old Hispanic man has a plasma glucose level of 142 mg per deciliter (7.9 mmol per liter) on initial evaluation and 139 mg per deciliter (7.7 mmol per liter) on reevaluation. Other than a steady gain in weight since college and borderline hypertension, his medical history is unremarkable. He is 175 cm (5 ft 9 in.) . . . [Full Text of this Article]

The Clinical Problem

Strategies and Evidence

Diet and Lifestyle Changes

Oral Agents

Insulin

Combination Therapy

Other Potential Approaches

Areas of Uncertainty

Guidelines

Conclusions and Recommendations

Source Information

From the Diabetes Center and the Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston.

Address reprint requests to Dr. Nathan at the MGH Diabetes Center, 50 Staniford St., Suite 340, Boston, MA 02114-2517.

Related Letters:

Initial Management of Glycemia in Type 2 Diabetes
Banarer S., Apolito R. A., Nathan D. M.
Extract | Full Text | PDF  
N Engl J Med 2003; 348:760-761, Feb 20, 2003. Correspondence

The Olivieri Case
Constantinou G., Melides S., Modell B., Spino M., Tricta F., Nathan D. G., Weatherall D. J.
Extract | Full Text | PDF  
N Engl J Med 2003; 348:860-863, Feb 27, 2003. Correspondence

This article has been cited by other articles:

• Chen, H.-S., Wu, T.-E., Jap, T.-S., Hsiao, L.-C., Lee, S.-H., Lin, H.-D. (2008). Beneficial Effects of Insulin on Glycemic Control and {beta}-Cell Function in Newly Diagnosed Type 2 Diabetes With Severe Hyperglycemia After Short-Term Intensive Insulin Therapy. Diabetes Care 31: 1927-1932 [Abstract] [Full Text]  
• Basu, R., Shah, P., Basu, A., Norby, B., Dicke, B., Chandramouli, V., Cohen, O., Landau, B. R., Rizza, R. A. (2008). Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People With Type 2 Diabetes. Diabetes 57: 24-31 [Abstract] [Full Text]  
• Pham, D. Q., Cohen, H., Chu, V. (2007). Inhaled Human [rDNA Origin] Insulin, a Novel Formulation for Diabetes Mellitus. J Clin Pharmacol 47: 890-903 [Abstract] [Full Text]  
• Malozowski, S. (2007). Exenatide in Combination Therapy: Small Study, Big Market, and Many Unanswered Questions. ANN INTERN MED 146: 527-528 [Full Text]  
• Gavin, J. R. III (2007). An Uncompromising Approach to Achieving Glycemic Goals. The Diabetes Educator 33: 52S-59S [Full Text]  
• Nathan, D. M. (2007). Counterpoint: No Time to Inhale: Arguments Against Inhaled Insulin in 2007. Diabetes Care 30: 442-443 [Full Text]  
• Hinnen, D., Nielsen, L. L., Waninger, A., Kushner, P. (2006). Incretin Mimetics and DPP-IV Inhibitors: New Paradigms for the Treatment of Type 2 Diabetes. J Am Board Fam Med 19: 612-620 [Abstract] [Full Text]  
• Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., Zinman, B. (2006). Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29: 1963-1972 [Full Text]  
• The STOPP-T2D Prevention Study Group, (2006). Presence of Diabetes Risk Factors in a Large U.S. Eighth-Grade Cohort. Diabetes Care 29: 212-217 [Abstract] [Full Text]  
• Meece, J. (2006). Dispelling Myths and Removing Barriers About Insulin in Type 2 Diabetes. The Diabetes Educator 32: 9S-18S [Full Text]  
• Marshall, M C Jr (2005). Diabetes in African Americans. Postgrad. Med. J. 81: 734-740 [Abstract] [Full Text]  
• Inzucchi, S. E. (2005). Metformin and Heart Failure: Innocent until proven guilty. Diabetes Care 28: 2585-2587 [Full Text]  
• Briggs, G. G., Ambrose, P. J., Nageotte, M. P., Padilla, G., Wan, S. (2005). Excretion of Metformin Into Breast Milk and the Effect on Nursing Infants. Obstet Gynecol 105: 1437-1441 [Abstract] [Full Text]  
• Oka, R. K, Umoh, E., Szuba, A., Giacomini, J. C, Cooke, J. P (2005). Suboptimal intensity of risk factor modification in PAD. Vasc Med 10: 91-96 [Abstract]  
• Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., Baron, A. D. (2005). Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea. Diabetes Care 28: 1083-1091 [Abstract] [Full Text]  
• DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D. (2005). Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes. Diabetes Care 28: 1092-1100 [Abstract] [Full Text]  
• Cochran, E., Musso, C., Gorden, P. (2005). The Use of U-500 in Patients With Extreme Insulin Resistance. Diabetes Care 28: 1240-1244 [Full Text]  
• Hirsch, I. B., Bergenstal, R. M., Parkin, C. G., Wright, E. Jr., Buse, J. B. (2005). A Real-World Approach to Insulin Therapy in Primary Care Practice. Clin. Diabetes 23: 78-86 [Full Text]  
• Lu, M., Kwan, T., Yu, C., Chen, F., Freedman, B., Schafer, J. M., Lee, E.-J., Jameson, J. L., Jordan, V. C., Cryns, V. L. (2005). Peroxisome Proliferator-activated Receptor {gamma} Agonists Promote TRAIL-induced Apoptosis by Reducing Survivin Levels via Cyclin D3 Repression and Cell Cycle Arrest. J. Biol. Chem. 280: 6742-6751 [Abstract] [Full Text]  
• Raskin, P., Allen, E., Hollander, P., Lewin, A., Gabbay, R. A., Hu, P., Bode, B., Garber, A., for the INITIATE Study Group, (2005). Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 28: 260-265 [Abstract] [Full Text]  
• Dixon, J. B., Pories, W. J., O'Brien, P. E., Schauer, P. R., Zimmet, P. (2005). Surgery as an Effective Early Intervention for Diabesity: Why the reluctance?. Diabetes Care 28: 472-474 [Full Text]  
• Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., for the Exenatide-113 Clinical Study Group, (2004). Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes. Diabetes Care 27: 2628-2635 [Abstract] [Full Text]  
• Yki-Jarvinen, H. (2004). Thiazolidinediones. NEJM 351: 1106-1118 [Full Text]  
• Ryan, E. A., Imes, S., Wallace, C. (2004). Short-Term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes. Diabetes Care 27: 1028-1032 [Abstract] [Full Text]  
• Koski, R. R. (2004). Oral Antidiabetic Agents: A Comparative Review. Journal of Pharmacy Practice 17: 39-48 [Abstract]  
• Kaput, J., Rodriguez, R. L. (2004). Nutritional genomics: the next frontier in the postgenomic era. Physiol. Genomics 16: 166-177 [Abstract] [Full Text]  
• Kelley, D. E., Kuller, L. H., McKolanis, T. M., Harper, P., Mancino, J., Kalhan, S. (2004). Effects of Moderate Weight Loss and Orlistat on Insulin Resistance, Regional Adiposity, and Fatty Acids in Type 2 Diabetes. Diabetes Care 27: 33-40 [Abstract] [Full Text]  
• Wolf, G., Ritz, E. (2003). Diabetic Nephropathy in Type 2 Diabetes Prevention and Patient Management. J. Am. Soc. Nephrol. 14: 1396-1405 [Full Text]  
• Banarer, S., Apolito, R. A., Nathan, D. M. (2003). Initial Management of Glycemia in Type 2 Diabetes. NEJM 348: 760-761 [Full Text]  
• White, J. R. Jr., Davis, S. N., Cooppan, R., Davidson, M. B., Mulcahy, K., Manko, G. A., Nelinson, D. (2003). Clarifying the Role of Insulin in Type 2 Diabetes Management. Clin. Diabetes 21: 14-21 [Abstract] [Full Text]